Ajanta Pharma Limited Stock

Equities

AJANTPHARM

INE031B01049

Pharmaceuticals

Market Closed - NSE India S.E. 07:40:29 2024-05-08 am EDT 5-day change 1st Jan Change
2,368 INR -1.26% Intraday chart for Ajanta Pharma Limited +5.98% +13.63%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 42.09B 504M Sales 2025 * 47.29B 566M Capitalization 299B 3.59B
Net income 2024 8.16B 97.76M Net income 2025 * 9.46B 113M EV / Sales 2024 6.67 x
Net cash position 2024 * 7.97B 95.48M Net cash position 2025 * 8.39B 100M EV / Sales 2025 * 6.16 x
P/E ratio 2024
34.4 x
P/E ratio 2025 *
32.1 x
Employees 7,713
Yield 2024 *
0.84%
Yield 2025 *
0.75%
Free-Float 50.31%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.17%
1 week+6.09%
Current month+6.98%
1 month+10.98%
3 months+7.59%
6 months+31.58%
Current year+13.74%
More quotes
1 week
2 210.00
Extreme 2210
2 540.00
1 month
2 051.60
Extreme 2051.6
2 540.00
Current year
1 998.35
Extreme 1998.35
2 540.00
1 year
1 246.75
Extreme 1246.75
2 540.00
3 years
1 061.77
Extreme 1061.7667
2 540.00
5 years
550.00
Extreme 550
2 540.00
10 years
265.36
Extreme 265.36
2 540.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 98-12-31
Chief Executive Officer 52 95-12-31
Director of Finance/CFO 59 98-04-22
Members of the board TitleAgeSince
Chief Executive Officer 52 95-12-31
Chairman 77 79-12-30
Director/Board Member 78 08-10-19
More insiders
Date Price Change Volume
24-05-08 2,368 -1.26% 155 535
24-05-07 2,398 -0.69% 190,565
24-05-06 2,415 +1.29% 364,670
24-05-03 2,384 +6.71% 2,771,320
24-05-02 2,234 +0.84% 83,782

Delayed Quote NSE India S.E., May 08, 2024 at 05:22 am EDT

More quotes
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2,398 INR
Average target price
2,440 INR
Spread / Average Target
+1.76%
Consensus
  1. Stock Market
  2. Equities
  3. AJANTPHARM Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW